British Lung Foundation   Report issue

Foundation Phase 2 Phase 3 Phase 4
Founded: London United Kingdom (1984)

Organization Overview

First Clinical Trial
2001
NCT00440687
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

British Lung Foundation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Diseases (Phase 4)

Lung Diseases, Obstructive (Phase 4)

Mesothelioma (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Tuberculosis (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 10